However, none of the existing screening programs have incorporated genetic testing for hereditary mutations, particularly pathogenic variants in the BRCA1/2 genes, despite their well-established role as major risk factors for breast and ovarian cancer (5–9). The gene discussed is BRCA1; the disease is ovarian carcinoma.